Neumora Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(177,478) | $(184,968) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 22,469 | 30,087 |
| Non-cash operating lease expense | 1,835 | 2,436 |
| Depreciation and amortization | 199 | 474 |
| Net accretion of investments in marketable securities | (2,797) | (4,638) |
| Impairment of held for sale assets | 378 | — |
| Non-cash interest expense and amortization of debt issuance costs | 516 | — |
| Other noncash expenses | 39 | 21 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 785 | 15,306 |
| Accounts payable | (2,759) | 5,770 |
| Accrued liabilities | 215 | 5,401 |
| Operating lease liabilities | (1,834) | (2,485) |
| Other assets | (53) | — |
| Net cash used in operating activities | (158,485) | (132,596) |
| Investing activities: | ||
| Purchases of marketable securities | (82,868) | (205,324) |
| Cash paid for acquisition of assets | — | (775) |
| Proceeds from maturities of marketable securities | 208,587 | 234,341 |
| Proceeds from sale of property and equipment | 171 | — |
| Purchases of property and equipment | (16) | — |
| Net cash provided by investing activities | 125,874 | 28,242 |
| Financing activities: | ||
| Net proceeds from term loan | 18,262 | — |
| Proceeds from exercise of stock options | — | 6,255 |
| Proceeds from employee stock purchase plan purchases | 59 | — |
| Payments for offering costs in connection with at-the-market offering and initial public offering | — | (225) |
| Net cash provided by financing activities | 18,321 | 6,030 |
| Net change in cash and cash equivalents and restricted cash | (14,290) | (98,324) |
| Cash and cash equivalents and restricted cash at beginning of year | 143,361 | 375,251 |
| Cash and cash equivalents and restricted cash at end of period | $129,071 | $276,927 |
| Components of cash and restricted cash: | ||
| Cash and cash equivalents | $129,071 | $275,714 |
| Restricted cash | — | 1,213 |
| Total cash and cash equivalents and restricted cash | $129,071 | $276,927 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $668 | $— |
| Cash paid for income taxes | $— | $473 |
| Offering costs in connection with at-the-market offering included in accrued liabilities | $— | $321 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Right-of-use-asset in connection with new operating lease agreement | $532 | $— |
| Operating lease liability in connection with new lease agreement | $505 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.